Karyopharm Therapeutics Q3 2026 Earnings Report

Karyopharm Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.16
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Karyopharm Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $33.54 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Karyopharm Therapeutics Announcement Details

• Quarter: Q3 2026
• Date: 11/2/2026
• Time: Before Market Opens
• Conference Call Date: Monday, November 2, 2026
• Conference Call Time: 8:00AM ET

Karyopharm Therapeutics (NASDAQ:KPTI) is a commercial-stage biopharmaceutical company focused on discovering and developing medicines that target nuclear transport proteins involved in cancer and other serious diseases. The company’s technology platform centers on selective inhibitors of nuclear export, particularly exportin 1 (XPO1), a protein that helps regulate the movement of key molecules between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is XPOVIO (selinexor), an oral XPO1 inhibitor. In the United States, XPOVIO is used in combination regimens for certain adults with relapsed or refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. The company has also evaluated selinexor in additional hematologic and solid-tumor cancers and continues to develop other investigational compounds based on its nuclear export platform.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm serves patients through commercial and development activities in the United States and international markets, supported by regulatory approvals and partnerships in selected regions. Its work is primarily focused on oncology, with research aimed at expanding the use of XPO1 inhibition and developing potential treatments for diseases with limited therapeutic options.